Purpose and Program Overview

The MRFF 2026 BioMedTech Incubator is a grant opportunity administered under the Medical Research Future Fund (MRFF), specifically within the Medical Research Commercialisation Initiative. The program provides grants of financial assistance to support medical research and medical innovation projects through the establishment of BioMedTech Incubators.

The opportunity looks to fund suitable organisations to identify, select, and support Australian small and medium enterprises (SMEs) undertaking early-stage medical research and medical innovation projects that have commercial potential. The program is designed to reduce the risk associated with early-stage research, bringing technologies to a stage where they are viable candidates for private investment and eventual commercialisation.

The intended outcome of the research funded by this grant opportunity is to improve the health and well-being of Australians by increasing the number of SMEs developing novel biomarkers, diagnostics, therapeutics, assistive devices and/or digital technologies that have progressed through the early stages of research and development to the point where they are ‘de-risked’ and attractive to private investment for commercialisation. Up to $132 million is available across the program in total.

Key Grant Details

• Grant amount per applicant: Up to $33 million
• Total program funding: Up to $132 million
• Application open date: 26 February 2026
• Application close date: Wednesday, 22 July 2026, at 5:00 pm AEST
• Eligible entity types: Medical research institutes, universities, corporate Commonwealth entities, and incorporated corporations (including not-for-profits)
• Location applicability: Organisations must be incorporated in Australia; the program is open nationally across all states and territories
• Co-contributions required: Applicants must demonstrate the capacity to meet project costs not covered by grant funding; no fixed co-contribution ratio is publicly specified, but financial evidence of this capacity is required
• ABN required: Yes

Priority Sectors

This program is specifically focused on the biomedical and health technology sector. Priority areas include:

• Novel biomarkers and diagnostics
• Therapeutics and assistive devices
• Digital health technologies

Applicants may propose to support development of innovations in their area(s) of strength — applicants are not required to propose a program that covers the breadth of the biomedtech sector. This means organisations with specialised expertise in one sub-sector may apply without needing to demonstrate capability across all areas listed above.

Funding Scope

• Maximum grant per application: $33 million
• Minimum grant: $0 (no stated minimum; the funding range is $0–$33 million per application)
• Total program pool: Up to $132 million
• Funding streams: A single funding stream is available under this opportunity; there are no separately defined sub-streams or categories
• Project timeline: The grant opportunity guidelines detail eligible project durations; applicants should consult the official guidelines for the maximum project period applicable to their proposed incubator program
• Purpose of funding: To establish and operate a functioning BioMedTech incubator that identifies, selects, and supports SMEs through early-stage research and development

Eligibility Criteria

To be eligible, applicants must have an Australian Business Number (ABN) and be incorporated in Australia. In accordance with Section 24 of the MRFF Act 2015, eligible entity types are the following:

• Medical research institutes
• Universities
• Corporate Commonwealth entities
• Corporations, including businesses and not-for-profit organisations

Organisations that are not eligible include the following:

• Individuals
• Partnerships
• Unincorporated associations
• Trusts (though an incorporated trustee may apply on behalf of a trust)
• Non-corporate Commonwealth entities
• Organisations included on the National Redress Scheme’s list of institutions that have not joined or signified their intent to join the Scheme
• Employers of 100 or more employees that have not complied with the Workplace Gender Equality Act (2012

Eligible Activities and Expenses

Grant funds must be directed towards the establishment and operation of a BioMedTech Incubator. Eligible activities and expenditures typically include:

• Identifying and selecting Australian SMEs with early-stage medical research projects for incubator participation
• Providing direct support to SMEs to progress research through development milestones
• Resourcing and managing incubator operations, including staffing, infrastructure, and program delivery
• Building partnerships with other research institutions, industry bodies, or commercialisation networks
• Activities that contribute to de-risking medical innovations to attract private investment
• Project management, reporting, and compliance activities associated with the grant

Applicants should refer to the official grant opportunity guidelines for a detailed and exhaustive list of eligible and ineligible expenditure items.

Assessment Process

This is a competitive, merit-based grant program. Eligible applications are assessed by an independent committee of experts, with the final funding decision made by the program delegate.

Assessment criteria are as follows:

• Assessment Criterion 1: Project Impact — weighted at 40%
• Assessment Criterion 2: Project Methodology — weighted at 30%
• Assessment Criterion 3: Capacity, Capability and Resources to Deliver the Project — weighted at 30%
• Assessment Criterion 4: Overall Value and Risk of the Project — non-weighted (considered holistically

Only applications that score satisfactorily against all criteria will be considered for funding. The amount of detail and supporting evidence provided should be proportionate to the project size, complexity, and grant amount requested.

Recent Program Updates

• The MRFF 2026 BioMedTech Incubator opportunity opened on 26 February 2026, representing the current funding round under the Medical Research Commercialisation Initiative.
• The program is part of a broader $152 million MRFF investment announced to support medical innovation, commercialisation, and consumer involvement in research.
• Total available funding of $132 million represents a significant commitment under the MRFF to developing Australia’s biomedtech SME pipeline.
• Applicants and interested organisations should monitor the Business.gov.au portal and GrantConnect (GO8128) for any updates to program guidelines before the closing date.

Application Tips

Organisations preparing an application for the MRFF 2026 BioMedTech Incubator should note the following:

• Confirm eligibility early. Verify that the entity type, ABN status, incorporation status, and Workplace Gender Equality Act compliance are all confirmed before commencing the application.
• Prepare mandatory documents in advance. Required documents include board or CEO approval evidence, a list of up to 15 Chief Investigators using the provided template, a detailed project plan (maximum 12 pages), a detailed and itemised project budget, a one-page statement of contribution to MRFF Measures of Success, a detailed risk management plan (maximum 2 pages), IP arrangements (if applicable), and letters of support from project partners (if applicable).
• Align the proposal with the MRFF strategic objectives. Clearly articulate how the proposed incubator will contribute to the MRFF’s Measures of Success and improve health outcomes for Australians.
• Focus on demonstrable capability. The assessment criteria place significant weight on the organisation’s capacity and resources to deliver the project. Applicants should provide concrete evidence of relevant experience, infrastructure, and team expertise.
• Do not submit incomplete applications. Applications cannot be corrected after submission, so all details and supporting evidence should be reviewed thoroughly before lodgement.
• Engage project partners early. If partner organisations are involved, secure letters of support well ahead of the closing date.
• Review the sample application form. This is available on the Business.gov.au portal and guides the character limits and level of detail expected.

Where to Get Help

Preparing a competitive application for a grant of this scale and complexity requires careful planning, thorough documentation, and a clear alignment with government priorities. Consider consulting a grant specialist like Pattens Group for a personalised eligibility assessment and expert assistance in preparing a strong, compliant, and competitive application. Contact us today and get connected with Australia’s best grant specialist, boasting over 35 years of experience in the industry and a 100% success rate.

For official guidelines, application details, templates, and further information, visit the official website of the MRFF 2026 BioMedTech Incubator at business.gov.au, GrantConnect (GO8128), and the Department of Health and Aged Care’s MRFF website.